Log in

NYSE:GKOSGlaukos Stock Price, Forecast & News

$38.98
-1.14 (-2.84 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$37.67
Now: $38.98
$40.49
50-Day Range
$32.34
MA: $36.12
$41.16
52-Week Range
$23.31
Now: $38.98
$84.65
Volume559,167 shs
Average Volume741,250 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Read More
Glaukos logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$236.98 million
Cash Flow$0.15 per share
Book Value$14.50 per share

Profitability

Net Income$15.42 million

Miscellaneous

Employees437
Market Cap$1.72 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

Glaukos (NYSE:GKOS) Frequently Asked Questions

How has Glaukos' stock been impacted by COVID-19 (Coronavirus)?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have increased by 0.9% and is now trading at $38.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Glaukos?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Glaukos.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Glaukos.

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) posted its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.09. The medical instruments supplier earned $55.30 million during the quarter, compared to analyst estimates of $55.05 million. Glaukos had a negative net margin of 15.65% and a negative return on equity of 6.95%. The business's revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the business posted ($0.04) earnings per share. View Glaukos' earnings history.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-55.3 million, compared to the consensus revenue estimate of $60.81 million.

What price target have analysts set for GKOS?

9 brokerages have issued 12-month price targets for Glaukos' shares. Their forecasts range from $34.00 to $67.00. On average, they expect Glaukos' share price to reach $47.63 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View analysts' price targets for Glaukos.

Has Glaukos been receiving favorable news coverage?

News headlines about GKOS stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Glaukos earned a news impact score of -5.0 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutGlaukos.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), NVIDIA (NVDA), PTC Therapeutics (PTCT), Paypal (PYPL), Marvell Technology Group (MRVL), Boeing (BA), Micron Technology (MU), Shopify (SHOP), Baidu (BIDU) and Caterpillar (CAT).

Who are Glaukos' key executives?

Glaukos' management team includes the following people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
  • Mr. Richard L. Harrison, Advisor (Age 62)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.22%), Brown Capital Management LLC (10.42%), Baillie Gifford & Co. (8.25%), Fred Alger Management LLC (6.47%), Janus Henderson Group PLC (5.41%) and State Street Corp (2.99%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends for Glaukos.

Which major investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invesco Ltd., Jennison Associates LLC, Wells Fargo & Company MN, Deutsche Bank AG, Rhenman & Partners Asset Management AB, and C WorldWide Group Holding A S. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and Thomas William Burns. View insider buying and selling activity for Glaukos.

Which major investors are buying Glaukos stock?

GKOS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Fred Alger Management LLC, State Street Corp, Bank of New York Mellon Corp, Wasatch Advisors Inc., Legal & General Group Plc, and Public Sector Pension Investment Board. View insider buying and selling activity for Glaukos.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $38.98.

How big of a company is Glaukos?

Glaukos has a market capitalization of $1.72 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.